TNYA Stock Forecast: Tenaya Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.29
−4.15% on the day

The median 12-month analyst price target for Tenaya Therapeutics, Inc. is $3.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 50 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$65.3M
Ticker Nerd rank
50/ 100
Median analyst target
$3.50
Analysts covering
6
Revenue$1.1M
Operating income−$20.9M
Net income−$43.4M
Free cash flow−$3.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−17.9%
1M
−30.1%
YTD
−59.7%
1Y
−75.3%
From 52W high
−79.7%
From 52W low
0.0%
$0.29
$1.41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Tenaya Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
50/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Revisions
75
Issuance
59
Growth
48
Value
30
Quality
29
Volatility
19
Momentum
6

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TNYA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TNYA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26TNYAHigh $6.00Median $3.50Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6
Buy
0
Hold
0
Sell
$2.00
Low
$3.50
Median
$6.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Mar 2026Chardan CapitalMaintainsBuy$8.00
18 Dec 2025Canaccord GenuityMaintainsBuy—
12 Dec 2025Chardan CapitalMaintainsBuy—
12 Dec 2025HC Wainwright & Co.MaintainsBuy—
10 Nov 2025Chardan CapitalMaintainsBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
27 Aug 2025HC Wainwright & Co.ReiteratesBuy—
7 Aug 2025Chardan CapitalMaintainsBuy—
9 May 2025Chardan CapitalMaintainsBuy—
25 Apr 2025HC Wainwright & Co.ReiteratesBuy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Mar 2025Canaccord GenuityMaintainsBuy—
12 Mar 2025Chardan CapitalMaintainsBuy—
12 Mar 2025Morgan StanleyMaintainsOverweight—
11 Mar 2025HC Wainwright & Co.MaintainsBuy—
3 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
18 Dec 2024Chardan CapitalMaintainsBuy—
18 Dec 2024HC Wainwright & Co.ReiteratesBuy—
26 Nov 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TNYA.

Market Radar

This page is one stock. Monday covers all of them.

TNYA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TNYA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Tenaya Therapeutics, Inc. returned −75.3% against +6.9% for the S&P 500, dividends included.

TNYA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26TNYAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TNYA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
21.5×

Cheaper than 7% of US stocks

Price / book
1.2×

Cheaper than 64% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
393.3%

Higher than 97% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−148.2%

Higher than 10% of US stocks

Return on assets
−55.4%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tenaya Therapeutics, Inc. has a market value of $65.3M and an enterprise value of $1.4M.

  • Revenue in the twelve months to 30 June 2026: $1.3M.

  • Net income over the same four quarters: −$103.1M, a −7724.0% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.53.

  • Free cash flow in the twelve months to 30 June 2026: −$52.6M.

  • Shares outstanding: 224.2M.

  • Tenaya Therapeutics, Inc. employs 70 people — $19K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

TNYA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TNYATenaya Therapeutics, Inc.$65.3M50
GOSSGossamer Bio, Inc.$65.5M65
CINGCingulate, Inc.$65.6M25
CRDFCardiff Oncology, Inc.$65.7M48
PMVPPMV Pharmaceuticals, Inc.$66.1M56
MNOVMediciNova, Inc.$64.4M88
PLYXPolaryx Therapeutics, Inc.$66.3M11

Take a look at TNYA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Tenaya Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TNYA

What is the TNYA stock price forecast for 2026-2027?

The median 12-month analyst price target for Tenaya Therapeutics, Inc. is $3.5, with estimates ranging from $2 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TNYA stock a buy right now?

Of the 6 analysts covering Tenaya Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tenaya Therapeutics, Inc. 50 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TNYA?

As at 21 Nov 2026, Tenaya Therapeutics, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will TNYA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts is $3.5, and Ticker Nerd's factor model ranks Tenaya Therapeutics, Inc. 50 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TNYA stock forecast for 2030?

No analyst covering Tenaya Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNYA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $6 over the next 12 months.

How has TNYA stock performed over the past year?

Tenaya Therapeutics, Inc. returned -75.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tenaya Therapeutics, Inc. do?

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for heart disease. The company’s current pipeline centers on gene therapy programs such as TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, along with TN-301, a small molecule HDAC6 inhibitor being studied for heart failure with preserved ejection fraction.

Company

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for heart disease. The company’s current pipeline centers on gene therapy programs such as TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, along with TN-301, a small molecule HDAC6 inhibitor being studied for heart failure with preserved ejection fraction. Tenaya Therapeutics also works through integrated platforms in gene therapy, cellular regeneration, and precision medicine to address the underlying drivers of inherited and other cardiovascular conditions. Headquartered in South San Francisco, California, the company serves the healthcare and biotechnology markets through research, discovery, and clinical development of cardiovascular treatments.

CEO Mr. Faraz Ali M.B.A. · 70 employees · United States · https://www.tenayatherapeutics.com